Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach

被引:10
作者
Ascoli, Valeria [1 ]
Minelli, Giada [2 ]
Cozzi, Ilaria [3 ]
Romeo, Elisa [3 ]
Scalzo, Caterina Carnovale [3 ]
Ancona, Laura [3 ]
Forastiere, Francesco [3 ]
机构
[1] Sapienza Univ, Dept Radiol Oncol & Anatomopathol Sci, Viale Regina Elena 324, I-00161 Rome, Italy
[2] Ist Super Sanita, Italys Inst Publ Hlth, Unit Stat, Viale Regina Elena 299, I-00161 Rome, Italy
[3] Lazio Reg Hlth Serv, Dept Epidemiol, Via Cristoforo Colombo 112, I-00147 Rome, Italy
关键词
Malignant pleural mesothelioma; Pathology reporting; Immunohistochemistry; Diagnosis; Cancer registry; EPITHELIOID MESOTHELIOMA; MINIMAL PANEL; IMMUNOHISTOCHEMISTRY; GUIDELINES; CANCER; ANTIBODIES; RECOMMENDATIONS; ADENOCARCINOMA; CONTROVERSIES; EXPRESSION;
D O I
10.1016/j.prp.2016.07.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Accurate pathologic diagnosis and reporting in malignant pleural mesothelioma are essential for clinical care, and cancer registration. Practical guidelines for pathologists are provided in publications and textbooks but it is unclear how these recommendations are applied in routine practice. We investigated the characteristics of pathology reports, and the extent to which they meet guideline standards. We reviewed 819 pathology reports relating to a first diagnosis of malignant pleural mesothelioma. Data sources were a regional section of the Italian network of the Mesothelioma Registry (2001-2014) and a pathology archive (1990-2000). We evaluated tumor characteristics, the diagnosis field including terminology and immunohistochemistry (IHC) workup, and report completeness (the proportion of items recorded). We investigated also two IHC panels identified by the most used markers in current practical guidelines, one best suited for epithelioid mesotheliomas (combinations of at least 2 positive and at least 2 negative mesothelioma markers) and the other best suited for sarcomatoid mesotheliomas (positive mesothelioma markers plus cytokeratins). Reports (753 histology, 66 cytology, IHC-confirmed 86%) were 74% complete and always narrative. Missing data were related to clinical history (76%), tumor laterality (61%), specimen size (38%), and histological subtype (23%). The proportion of cases with IHC was higher for epithelioid (90%) than sarcomatoid mesothelioma (87%). Compliance to IHC recommendations was higher for epithelioid (59%) than sarcomatoid mesothelioma (11%). The mean number of stains was significantly higher for sarcomatoid than epithelioid mesothelioma (p<0.000; Kruskal-Wallis test). Our findings show that although guidelines are designed to improve actual reporting practices, there is ample room for improvement in their application to standardize the diagnosis of mesothelioma. Synoptic pathology reporting needs to be implemented to better utilize pathology information. (C) 2016 Elsevier GmbH. All rights reserved.
引用
收藏
页码:886 / 892
页数:7
相关论文
共 50 条
  • [1] Pathology of Malignant Pleural Mesothelioma
    Hung, Yin P.
    Chirieac, Lucian R.
    THORACIC SURGERY CLINICS, 2020, 30 (04) : 367 - 382
  • [2] Malignant Pleural Mesothelioma A Population-Based Study of Survival
    Milano, Michael T.
    Zhang, Hong
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) : 1841 - 1848
  • [3] Cytological diagnosis of malignant pleural mesothelioma
    Siaw Ming Chai
    Chris Van Vliet
    Current Pulmonology Reports, 2017, 6 (1) : 1 - 8
  • [4] Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review
    Linton, Anthony
    Kao, Steven
    Vardy, Janette
    Clarke, Stephen
    van Zandwijk, Nico
    Klebe, Sonja
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (03) : 273 - 279
  • [5] A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit
    Segal, Amanda
    Sterrett, Gregory F.
    Frost, Felicity A.
    Shilkin, Keith B.
    Olsen, Nola J.
    Musk, Arthur William
    Nowak, Anna K.
    Robinson, Bruce William S.
    Creaney, Jenette
    PATHOLOGY, 2013, 45 (01) : 44 - 48
  • [6] Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis
    Bruno, Rossella
    Ali, Greta
    Giannini, Riccardo
    Proietti, Agnese
    Lucchi, Marco
    Chella, Antonio
    Melfi, Franca
    Mussi, Alfredo
    Fontanini, Gabriella
    ONCOTARGET, 2017, 8 (02) : 2758 - 2770
  • [7] Updates in the diagnosis and treatment of malignant pleural mesothelioma
    Katzman, Daniel
    Sterman, Daniel H.
    CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (04) : 319 - 326
  • [8] The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review
    Ali, Greta
    Bruno, Rossella
    Fontanini, Gabriella
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S276 - S284
  • [9] Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
    Hjerpe, Anders
    Own, Sulaf Abd
    Dobra, Katalin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 934 - 943
  • [10] Does Size Matter? A Population-Based Analysis of Malignant Pleural Mesothelioma
    He, J.
    Shen, J.
    Pan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S747 - S748